Intended for US healthcare professionalsVisit Patient SiteFull Prescribing InformationImportant Safety InformationSign Up
Share via:
  • Share via Email icon
  • Linkedin Logo
WAKIX Prescription
Referral Form
Live Support855-WAKIX-INFO
Why WAKIX

WAKIX Overview

Play Icon

Chris Winter, MD

Board-certified neurologist and sleep specialist

  • Different mechanism of action
  • Not a controlled substance
  • Evaluated in multiple clinical studies and FDA approved in 2019
  • Treats both excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy
  • Established safety and tolerability profile in clinical studies
  • Strong recommendation for the treatment of narcolepsy in adults in the American Academy of Sleep Medicine (AASM) Clinical Practice Guideline* (clinically significant improvement in EDS and cataplexy)1

    *Clinical practice guideline on the treatment of central disorders of hypersomnolence, published in the Journal of Clinical Sleep Medicine.

See how WAKIX is thought to work»View EDS and cataplexy clinical data»

Reference

  1. AASM Task Force. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881-1893.